Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nursing Diagnosis01:22

Nursing Diagnosis

Following assessment, a nursing diagnosis is the next step in the nursing process. It begins after the nurse has collected and recorded the patient data. The purpose of diagnosing is to identify how the client responds to actual or potential health processes, identify factors that bestow or that cause health problems, the etiologies, and identify resources or strengths the individual, group, or community can draw on to prevent or resolve problems.
The nursing diagnosis focuses on evidence-based...
Methods of Documentation IV: Focus Charting01:26

Methods of Documentation IV: Focus Charting

Focus Charting, also known as the focus charting system or "focus documentation," is a systematic documentation approach used in healthcare to organize patient information in medical records.
It typically involves three columns for recording information:
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic illness...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses.

The journal of prevention of Alzheimer's disease·2026
Same author

Go-Along Virtual INTERview (GVIv): A Novel Nurse-Led Qualitative Method for Exploring Neighborhood Lived Experience and Health.

Global qualitative nursing research·2026
Same author

Comment on: The impact of psychological trauma on weight loss, psychosocial functioning, and psychopathology in bariatric and metabolic surgery candidates: a systematic review.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery·2026
Same author

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial.

Neurology. Clinical practice·2026
Same author

Characterizing the Diffusion Properties of Prostate Tissue Using Paired MR Microscopy and Multidimensional Diffusion MRI.

Magnetic resonance in medicine·2026

Related Experiment Video

Updated: Jul 7, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

How donanemab data address the coverage with evidence development questions.

Eric G Klein1, Krista Schroeder2, Alette M Wessels2

  • 1Global Medical Affairs, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|February 7, 2024
PubMed
Summary
This summary is machine-generated.

Donanemab significantly slowed cognitive decline in early Alzheimer's disease (AD) patients. The drug demonstrated a manageable safety profile, supporting reconsideration of coverage for AD treatments.

Keywords:
Alzheimer's diseaseCenters for Medicare and Medicaid ServicesCoverage with Evidence DevelopmentMedicareNational Coverage Determinationamyloid‐related imaging abnormalitiesamyloid‐targeting therapyanti‐amyloid monoclonal antibodybrain hemorrhagecerebral edemacognitive and functional declinedementiadonanemabearly symptomatic Alzheimer's diseasehealth outcomesmild cognitive impairmenttau

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.8K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.5K

Related Experiment Videos

Last Updated: Jul 7, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.8K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.5K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Alzheimer's disease (AD) poses a significant challenge, necessitating effective treatments.
  • The Centers for Medicare & Medicaid Services (CMS) established Coverage with Evidence Development (CED) criteria for amyloid-targeting monoclonal antibodies in AD.
  • Donanemab is an investigational monoclonal antibody targeting amyloid plaques.

Approach:

  • This review analyzes data from the TRAILBLAZER-ALZ trials for donanemab.
  • Evidence from supporting literature and real-world data is integrated.
  • The analysis directly addresses the three CED questions set by CMS.

Key Points:

  • Donanemab demonstrated statistically significant slowing of cognitive and functional decline in early symptomatic AD patients with confirmed amyloid positivity.
  • The treatment lowered the risk of disease progression.
  • Key safety risks, primarily amyloid-related imaging abnormalities (ARIA), occurred mainly within the first six months and subsequently declined with monitoring.

Conclusions:

  • Donanemab shows meaningful improvement in health outcomes for early symptomatic AD, with a manageable safety profile.
  • Trial participant demographics, comorbidities, and co-medications align with the broader Medicare population.
  • The presented evidence supports a reconsideration of the current National Coverage Determination (NCD) for donanemab.